Physician profile
Jeffrey L Sutton
NPI 1942259148
$2,773.85
in general payments reported to CMS, 2019-2025
21 companies · $926 in 2025
The $926 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $135 · 2021: $84.60 · 2022: $317 · 2023: $263 · 2024: $535 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,691 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,691.17 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $455.23 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $303.01 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $302.83 | 2020-2025 | |
| Biotronik INC. | $302.21 | 2019-2025 | |
| W. L. Gore & Associates, INC. | $186.34 | 2019 | |
| Janssen Pharmaceuticals, INC | $184.16 | 2021-2024 | Xarelto |
| Astellas Pharma US INC | $182.98 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $175.57 | 2020-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $125.69 | 2024-2025 | |
| Boston Scientific Corporation | $106.33 | 2021-2025 | Watchman Flx, Watchman Access System |
| Medtronic, INC. | $105.16 | 2021-2023 | Micra |
| Merck Sharp & Dohme LLC | $88.89 | 2023-2025 | Verquvo |
| Heartflow, INC. | $46.15 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $41.27 | 2024-2025 | Camzyos |
| Esperion Therapeutics, INC. | $40.54 | 2024 | Nexletol |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $30.19 | 2025 | |
| Novartis Pharmaceuticals Corporation | $20.50 | 2024 | |
| Amarin Pharma, INC. | $20.49 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.80 | 2025 | Jardiance |
| Lilly USA, LLC | $19.74 | 2025 | Zepbound |
| Abbott Laboratories | $16.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.